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Abstract
As with many pathogens, most dengue infections are subclinical and therefore unobserved1. 
Coupled with limited understanding of the dynamical behavior of potential serological markers of 
infection, this observational problem has wide-ranging implications, including hampering our 
understanding of individual- and population-level correlates of infection and disease risk and how 
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they change over time, assay interpretation and cohort design. We develop a framework that 
simultaneously characterizes antibody dynamics and identifies subclinical infections via Bayesian 
augmentation from detailed cohort data (3,451 individuals with blood draws every 91 days, 
143,548 hemagglutination inhibition assay titer measurements)2,3. We identify 1,149 infections 
(95% CI: 1,135–1,163) that were not detected by active surveillance and estimate that 65% of 
infections are subclinical. Post infection, individuals develop a stable setpoint antibody load after 
1y that places them within or outside a risk window. Individuals with pre-existing titers of ≤1:40 
develop hemorrhagic fever 7.4 (95% CI: 2.5–8.2) times as often as naïve individuals compared to 
0.0 times for individuals with titers >1:40 (95% CI: 0.0–1.3). PRNT titers ≤1:100 were similarly 
associated with severe disease. Across the population, variability in the force of infection results in 
large-scale temporal changes in infection and disease risk that correlate poorly with age.
Despite the large body of literature from observational and cohort studies describing dengue 
cases, we still have major difficulties in explaining individual- and population-level 
differences in infection and disease risk. These difficulties largely come from a fundamental 
methodological issue in the research of many pathogens that individual histories of infection 
are difficult to capture. The four dengue virus serotypes (DENV1–4), which are found across 
tropical and sub-tropical regions with an estimated 390 million infections each year, cause a 
range of disease manifestations, from asymptomatic infection to death4,5. High levels of 
subclinical infection mean that even in environments of thorough active surveillance, the 
majority of infections are missed1. This observational problem has wide ranging 
implications as it hampers our ability to estimate the underlying level of infection in the 
community, to characterize individual risk factors for infection and severity but also to 
assess correlates of protection, to dynamically monitor susceptibility at both the population 
and individual level, to define optimal thresholds for the interpretation of serological assays 
or to critically assess cohort design.
Here, we develop an analytical framework that can address this challenge, leading to new 
insights on a broad range of questions. We use it to jointly characterize antibody changes 
following infection and identify infection events missed by surveillance from the analysis of 
longitudinal data from cohort studies. We apply it to data from a school-based cohort study 
in Thailand (N=3,451, mean age at recruitment of 9y, interquartile range 8–11) where blood 
was taken on average every 91 days for up to five years and when illnesses were detected 
through active surveillance2. Active fever and school absence surveillance was conducted 
during June to mid-November when DENV circulation is concentrated2. Hemagglutination 
inhibition (HI) tests were used to measure antibody titers to each serotype in each sample 
(143,548 HI measurements in all). PRNT titers were also measured on a subset of 1,771 
samples. HI titers correlate closely with PRNTs (Pearson correlation of 0.91) and with 
inhibition ELISAs, although titer values differ by laboratory and assay6–9.
To track the evolution of an individual’s measured antibody titers (Figure 1A), we place 
titers on an adjusted log2 scale (titers of 1:10 are given a value of 1, 1:20 of value of 2 etc.). 
There were 274 detected symptomatic DENV infections (Figure 1B); 62 were hospitalized 
(23%), 36 with dengue hemorrhagic fever (DHF) (13%). For those where the infecting 
serotype is known (79% of cases through PCR, Table S1), we observe a sharp rise and 
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subsequent decay in log2-titers following symptom onset (Figure 1C–D). The mean log2-
titer to the infecting serotype was 0.79 (95% CI: 0.74–0.84) times the log2-titer to the non-
infecting serotype in the three months prior to symptom onset compared to 0.94 (95% CI: 
0.93–0.96) times in the six months after symptom onset (Figure 1E). As 86% of 
symptomatic infections had detectable titers to at least one serotype prior to infection, the 
higher antibody titer to non-infecting serotypes likely captures responses to prior 
infections10.
We reconstruct individuals’ antibody trajectories by assuming that infection leads to a rise in 
titers that subsequently decays exponentially11. We also explore biphasic responses 
(Extended Data Figure 1). We allow for variability in antibody kinetics across individuals 
and infections, and for differential rises for the infecting versus the non-infecting serotypes 
for primary infections but undifferentiated responses for subsequent infections. We use data 
augmentation techniques to impute undetected infections (subclinical infections during 
active surveillance or unknown symptom status outside the surveillance windows) and to 
identify the serotype for undetected primary infections3. Instead of relying on fixed cutoffs 
to identify infections, data augmentation allows us to incorporate uncertainty in the 
existence, timing and serotype of unobserved infection events and therefore probabilistically 
assess whether differences in measured titers are due to infections or assay variability.
We find that following post-primary infection there is a mean 5.8 (95% CI: 5.6–5.9) rise in 
log2-titers across serotypes, which declines by 76% after one year. For primary infections 
(i.e., individuals without detectable titers prior to infection) the mean log2-titer rise is 7.6 
(95% CI: 7.4–7.8) for the infecting serotype and 6.6 for the non-infecting serotypes (95% 
CI: 6.4–6.7). The similarity of titers of infecting and non-infecting serotypes coupled with 
assay variability suggests that in a clinical setting individual HI measurements cannot 
reliably determine the infecting serotype. We find that titers largely stabilize one year after 
infection to a set-point (the ‘set-point antibody load’) (Figure 1D). There is significant 
variability between infections: the interquartile range of the log2-titer rise one year after 
infection is 0.7–2.2 across all infections (Extended Data Figure 2A). We find that even after 
accounting for historic infection status, measured DENV-2 titers are systematically lower 
than other serotypes (0.85 lower than DENV1) (Extended Data Figure 2B, Table S2), which 
could point to technical considerations of the DENV2 assay or inherent differences in 
immune responses to DENV2. We estimate the measurement error in the HI assay (i.e., the 
standard deviation in any reading) as 0.49 (95% CI: 0.49–0.50), which is similar with that 
empirically estimated using repeated testing on the same serum and 2.6 times error estimates 
for the plaque reduction neutralization test (PRNT) (Extended Data Figure 2C)12. Despite 
the variability in individual readings, as we use many readings from four serotypes for each 
participant and titers appear to behave in a stable and predictable manner, we can 
nevertheless make robust inferences when considering the ensemble of the measurements.
We probabilistically identify 1,149 undetected infections (95% range across model 
iterations: 1,135–1,163), of which 507 (494–520) occurred during active surveillance 
periods and were therefore subclinical (Figure 1B). Overall, we estimate 35% of infections 
are symptomatic (95% CI: 34–36). The temporal distribution of subclinical infections was 
correlated with that of symptomatic infections (Pearson correlation 0.78, 95% CI: 0.70–
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0.84). Using augmented primary infections where we could confidently assign the infecting 
serotype (same serotype implicated by >50% of iterations), we find that 34% of undetected 
primary infections (and 39% of subclinicial primary infections) were due to DENV-4, 
compared to only 3% of all symptomatic infections (none of which were primary infections) 
(Extended Data Figure 3A–B). We find consistent results using a more stringent cutoff to 
assign the infecting serotype (Extended Data Figure 3C). These findings are consistent with 
a reduced risk of disease from DENV-4 compared to other serotypes resulting in a largely 
silent DENV-4 epidemic. This is supported by a phylogenetic analysis that found DENV-4 
was widespread in Thailand throughout this period (Figure S4 in Salje et al.,13). This 
suggests the serotype distributions from hospital-based or community-based surveillance 
may not be representative of infections in the population and supports previous evidence that 
the transmissibility of a serotype can be delinked from the propensity to cause symptomatic 
and/or severe disease14,15. Further they imply that factors that contribute to transmission 
potential (e.g., viral replication, peak titers or infection length) are not predictive of adverse 
outcomes16.
We find that the underlying probability of infection and the probability of developing disease 
are strongly linked to the mean antibody titer at the time of exposure. Overall, an 
individual’s annual risk of infection was 17%, varying from 21% for individuals with mean 
measured log2-titers <2, to 16% for those with log2-titers of 2–3 and 11% for those with 
log2-titers of >3 (Figure 2A). Using logistic regression, we find that for log2-titers >2, each 
unit increase in log2-titers is associated with a 0.71 times relative risk of infection (95% CI: 
0.67–0.76). The annual probability of having a symptomatic infection varies from 6.4% 
(95% CI: 4.9–8.4) for primary infections to 8.4% (95% CI: 7.8–9.1) for individuals with pre-
existing log2-titers ≤3 (≤1:40 on a linear scale) and 4.0% (95% CI: 3.0–5.0) for those with 
log2-titers >3 (Figure 2B). The annual probability of being hospitalized during a primary 
infection was 1.2% (95% CI: 0.5–2.1), compared to 2.4% (95% CI: 2.1–2.7) during a 
subsequent infection for those with pre-existing log2-titers ≤3 and 0.3% for those with log2-
titers >3 (95% CI: 0.09–0.6) (Figure 2C). Even more stark was the risk for developing DHF, 
which ranged from 0.2% (95% CI: 0.0–0.6) for primary infections compared to 1.5% (95% 
CI: 1.3–1.7) for subsequent infections in those with log2-titers ≤3 and 0.0% for log2-titers >3 
(95% CI: 0.0–0.4) (Figure 2D). Within this study population, an average of 54% of the 
population had detectable log2-titers of ≤3 at any time. Time-varying cox proportional 
hazards models that specifically account for the dependence of titer observations within 
individuals gave similar results (Extended Data Figure 4)17. Using log2-titers to 
probabilistically identify the cohort participants with detectable titers that will develop DHF 
has an AUC of 0.66 (Extended Data Figure 5).
Considering only infected individuals, we observe no difference in the probability of 
subclinical infection by titer; however, the probability of hospitalization and DHF remains 
greatest in those with pre-existing log2-titers of ≤3 (Extended Data Figure 6A–C). Only one 
individual with pre-infection log2-titers >3 developed DHF during surveillance compared to 
146 who did not but had titers at infection within the same range. This suggests that in the 
event that infection takes place, antibodies are not protective of developing symptoms per se 
but, conversely, are associated with the development of severe disease. We observe no 
difference in the risk of disease given infection across years (Table S3) or age (Table S4). 
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Other studies are needed to see if younger age groups than those included here nevertheless 
have increased risk. PRNTs form the basis of current discussions on immune correlates. 
Among those infected, individuals with detectable PRNT log2-titers of ≤4.5 (equivalent to 
approximately ≤1:100) have 7.5 times (95%CI: 2.4–11.6) increased risk of DHF compared 
to previously naïve individuals, compared to 0.0 times for those with higher titers (Extended 
Data Figure 6D–F). Cross-reactive titers that result from exposure to non-DENV flaviviruses 
such as Japanese encephalitis and Zika may be included in these risk estimates.
Our findings suggest that post-infection set-point antibody loads appear important to 
determining individual infection and disease risk. Post infection, we estimate the daily 
probability of a subsequent infection and the development of DHF disease as a function of 
titer dynamics. We demonstrate that the probability of both infection and disease stabilizes 
after 1y (Figure 3). Based on our observation in Figure 2 that individuals with detectable 
titers of ≤3 had increased risk of infection and disease, we explored the temporal evolution 
of risk following infection for those with setpoint antibody loads (i.e., the titer at 1y 
following infection) above and below this threshold. At 1 year, we observe a 2.1 times 
increased risk of infection (irrespective of disease outcome) for those with setpoint antibody 
loads of ≤3 compared to those with greater antibody loads and an 8.9 times increased risk of 
infection that leads to DHF. Overall, we find that three years following infection 34% of 
individuals with setpoint antibody loads of ≤3 suffer a subsequent infection, irrespective of 
severity (95% CI: 33%–35%) compared to 23% for those with greater loads (95%CI: 20%–
26%). After this delay 3.5% of individuals with setpoint loads of ≤3 develop DHF disease 
(2.4%–4.4%) compared to none in those with higher loads. The apparent stability of setpoint 
antibody loads points to an ability to assess an individual’s long-term risk.
Our findings are consistent with low titers generated by some candidate vaccines in 
previously naïve individuals ‘priming’ individuals for severe disease upon their first 
exposure18. A hypothesis supported by previous evidence that primary infections in infants 
with maternal antibodies and secondary infections in older individuals are associated with 
severe disease19,20. Further, a Nicaraguan study found elevated risk of severe disease for 
those with low iELISA titers at prior annual blood draws9. Previously naïve individuals 
given the Dengvaxia vaccine had mean PRNT titers within our risk window (Figure 4D)21. 
Further work is required to understand whether immunity acquired from vaccination and 
natural infection are qualitatively similar and whether the risk window described here is 
relevant for vaccine recipients. T-cell immunity, which is not captured by these assays, might 
compensate for antibody titers in this window. Vaccine studies should carefully assess the 
criteria used to define seroconversion, and how titers correlate with disease risk over time. 
Our work suggests that previously used criteria (PRNT titer >1:10) do not adequately 
correlate with reduction in disease risk and suggest that HI titers >1:40 or PRNT titers of 
>1:100 may provide a starting point for any vaccine in identifying a targeted neutralizing 
antibody response. Placebo arm data from the Dengvaxia vaccine trials also suggests higher 
PRNT titers are linked to protection 22. The targeted vaccination of individuals that have 
pre-existing antibody titers within our zone may be a viable approach to minimize the public 
health burden from dengue by moving individuals away from the risk window (Figure 4D). 
Even in an endemic setting such as our cohort, there is considerable temporal variability in 
the serological status of 9y individuals (Extended Data Figure 7) suggesting that the current 
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WHO guidance surrounding Dengvaxia or similar guidance based on serostatus at 
vaccination will have to carefully consider this variation or specifically screen individuals.
Our approach allows us to consider wider problems concerning drivers of dengue 
epidemiology. The assumption that population-wide immunity varies in time and dictates 
multi-annual dynamics of dengue pervades the literature and dominants current hypotheses 
about what drives large outbreaks of dengue in particular settings18,23–26. More generally, 
the idea that temporally varying population immunity drives temporal dynamics of 
pathogens pervades infectious disease epidemiology27–29. However, quantitative evidence 
that any population varies in dengue immune status over time is largely lacking, as is a link 
between the immune status of a population and the risk of epidemics in empirical data. Here, 
though we have only a short time series, we show that underlying heterogeneity in the size 
of annual epidemics mean the risk of having titers within-the risk zone for different birth-
cohorts are more correlated by epidemic time-point (Figure 4A, mean correlation of 0.70) 
than by age (Figure 4B, mean correlation of 0.23). While both the probabilities of being 
naïve and having log2-titers above the risk-zone are correlated with age, there also exist 
strong birth-cohort effects (Extended Data Figure 7). For example, among 9 year olds, we 
observe up to a two-fold difference in the probability of being naive, depending on the year 
of the study.
Finally, our results can guide the design of cohort studies aiming to characterize 
transmission. Studies typically use a four-fold rise in titers against any serotype as evidence 
of infection, regardless of the timing of sample collection. Using our titer trajectories, we 
find that if blood draws are every 90 days, a four-fold cut-point on measured titers has a 
specificity of >99% and a sensitivity of 87% (Figure 4C, Extended Data Figure 8). The 
sensitivity is reduced to 77% when blood is taken every six months and 62% when blood is 
taken annually, although it may be higher in seasonal settings when samples are taken at the 
season’s end. Using an alternative approach that uses the mean titer across the four serotypes 
and a 1.6-fold cut-point, the sensitivity of the assay improves to 96% when samples are 
taken every six months and to 90% for annual bleeds (specificity >95%) (Extended Data 
Figure 9). We provide the optimum cut-point and estimated sensitivity for these approaches 
and a theoretical one where titers are on a continuous scale (such as PRNT) and where a 
minimum specificity of >99% is required (Extended Data Figure 9).
We demonstrate through simulation that our framework can recover the true number of 
subclinical infections and parameters when only 30% of infections are symptomatic (Table 
S5). Our approach is also robust to a scenario where there are differential rises in titers for 
symptomatic and non-symptomatic infections (Table S6) and where we incorporate school 
specific force of infection parameters (Table S7). In addition, we find the timing (Extended 
Data Figure 10A) and the serotype (Extended Data Figure 10B) of undetected infections 
cluster in the same locations as symptomatic infections. This provides strong support of our 
modeling framework by suggesting that the model can correctly identify spatio-temporal 
clustering of otherwise undetected infections. These findings also support focal 
transmission, irrespective of disease outcome13,30,31. The approach presented here will be 
applicable across disease systems where longitudinal titer data exists, allowing a wide range 
of insights into fundamental questions of disease ecology and risk.
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1. Cohort study design
Individuals attending 12 different schools in Kamphaeng Phet district, a rural region of 
Northern Thailand were recruited into a dengue cohort study that ran between 1998 and 
2003 as previously described32. All individuals were between seven and 13 years old. Blood 
samples were taken four times a year (in January, June, August and November) with an 
average of 91 days between blood draws. In addition, from the start of June to mid 
November each year, active surveillance was conducted through school-based surveillance. 
Children who missed school due to febrile illness had additional acute and convalescent 
blood draws. Dengue infection was confirmed using RT-PCR on the acute sample, with the 
infecting serotype also recorded or through antibody detection (IgM ELISA values >40 or 
HI rises of over four times between acute and convalescent blood draws), in which case the 
infecting serotype was not known. The date of symptom onset, whether or not the child was 
hospitalized and whether or not they developed DHF was also recorded. Note that the cohort 
study was conducted prior to 2009 when the WHO provided new guidance of the 
characterization of different levels of dengue severity.
2. Antibody measurements
For each individual’s blood draw, antibody titers to each of DENV1, DENV2, DENV3, and 
DENV4 were measured using a hemagglutination inhibition assay. The following two-fold 
dilutions were used: 1:10, 1:20, 1:40, 1:80, 1:160, 1:320, 1:640, 1:1280 and 1:2560. We 
translated each titer onto a log2 scale such that 1:10 was given a value of 1, 1:20 of value of 
2 and so on. Undetectable titers (those with a titer of <1:10) were given a value of 0. For a 
subset of 800 individuals, 1,771 samples were also tested using plaque reduction 
neutralization tests (PRNTs). These samples were either paired samples from individuals 
with symptomatic confirmed infection with one sample taken from a time point prior to 
symptom onset and one sample from post symptom onset (N=75 pairs) or randomly chosen 
sequential blood samples from individuals without a detected symptomatic infection 
between the blood draws.
3. Characterizing how titers change following symptomatic infection
We can understand how titers to both the infecting serotype and to non-infecting serotypes 
change over time prior to and following symptom onset. For all individuals that experienced 
a symptomatic illness where the infecting serotype was identified, we identify all titer 
measurements within each 10-day window from 100 days prior to symptom onset to 600 
days post symptom onset. For each window, we calculate the mean titer to the infecting 
serotype and the average mean titer to the other three serotypes across all individuals that 
had a blood draw within that window.
4. Modeling the dynamics of dengue antibody titers
Previous efforts in malaria have used hidden Markov models to include undetected 
infections in estimates of the transmission intensity using presence/absence of specific 
antibodies in longitudinal data33. While these efforts are able to improve estimates on the 
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force of infection within a community compared to using symptomatic individuals, they do 
not incorporate the changing dynamics of antibody titers over time. By specifically including 
titer dynamics, we can help understand a wide range of issues, including assay error, 
measures of protection and risk and cohort design.
4.1. Notation—We consider an individual i. We denote ni
I(t) the number of times the 
individual was infected prior to time t. Each dengue infection of individual i is labeled by the 
index ψ = 1…ni
I(t). We denote τi, ψ
I  the time of infection number ψ of individual i and si, ψ 
the infecting serotype of infection number ψ of individual i. The history of infection (i.e., 
the timing and serotype of all infections since birth) of individual i up to time t is labeled 
Hi(t). We denote Ni
A the total number of times the individual had blood taken during the 
study. Each blood draw of individual i is labeled by the index π = 1…Ni
A. We denote τi, π
A  the 
time of blood draw π for individual i. We denote Ai, s, π the true antibody titer (see Section 
4.3) and Ai, s, π
∗  the measured antibody titer for individual i for serotype s at blood draw π. 
Λi(t) represents the cumulative force of infection exerted on individual i prior to time t. The 
parameter vector is denoted by θ.
4.2. Hierarchical structure of the model—We can break down the probability of a 
measured antibody titer into three components:
P Ai, s, π = k
∗ Ai, s, π = k
· P Ai, s, π = k τi, ψ = 1
I , …τ
i, ψ = ni
I(t = τi, π = k
A )
I , si, ψ = 1, …si, ψ = ni
I(t = τi, π = k
A )
, Ai, s, π = 1,
…Ai, s, π = k − 1
· P Hi(t = τi, π = k
A ) {λ}t
The first part represents the ‘measurement model’, the second part the ‘antibody dynamics 
model’ and the third part the ‘infection model’.
4.3. Measurement model—We model the underlying antibody levels on a continuous 
scale, however, the hemagglutination inhibition assay is a discrete assay, such that in a 
situation of no measurement error or systematic biases, a true antibody titer between any two 
dilutions would be measured as the lower of the two dilutions. So for example, a true titer of 
2.7 would be measured as 2 (assuming there are dilutions performed at 0,1,2,3…). In 
addition, there is also likely to exist measurement error and there may be underlying 
differences by serotype (i.e., serotype-specific biases) in the assay that will impact all 
measurements of antibodies against a particular serotype. We consider a ‘true titer’ to 
represent the underlying (but unmeasured) titer on a continuous scale. A ‘measured titer’ is 
the value that is actually measured by the assay. Conditional on an individual’s history of 
Salje et al. Page 8













infection, we assume independence between the measurements of the different serotypes. 
This seems a reasonable assumption as assays are performed separately for each serotype. 
The probability of the measured titers, Ai, s, π = k
∗  is:
P Ai, s, k




where f(u) is the density for a normal distribution with mean Ai, s, k + χs and a standard 
deviation parameter, σ. Where:
χs = 0 if s = DENV1
χs = χ2 if s = DENV2
χs = χ3 if s = DENV3
χs = χ4 if s = DENV4
4.4. Antibody dynamics model—If an individual i was never infected by dengue, we 
assume they will have titers of 0 against the four serotypes (this assumes any maternal 
antibodies have disappeared and there is no impact of infections by other flaviviruses). At 
each time point that the individual becomes infected, their antibody titers will rise. We 
assume that the rise can be broken down into a permanent increase (representing antibodies 
that will continue to circulate, long after the infection has passed) and a temporary increase 
(representing the short-lived antibodies generated upon infection).
4.4.1. Permanent rise in titers: The permanent rise in titers Qi, s(ψ), for serotype s from 
infection number ψ in individual i is modeled as:
Qi, s(ψ) = ωi, ψ · K(ψ , s)
where ωi, τ is a random effect that is gamma distributed with mean parameter ωm and 
variance parameter ωv and K(ψ, s) allows differential antibody response by serotype for 
primary infections: K(ψ, s) = η if it is a primary infection (i.e., ψ=1) and s is the infecting 
serotype; K(ψ, s) = 1 otherwise.
4.4.2. Temporary rise in titers: We assume that temporary antibody responses will decay 
exponentially over time:
Ri, s(t ∣ Hi(t)) = γi, ψ = ni
I(t)
· exp − t − τ
i, ψ = ni
I(t)
I · δ
i, ψ = ni
I(t)
· K(ψ = ni
I(t), s)
where γ
i, ψ = ni
I(t)
 is a random effect that captures the instantaneous rise in temporary 
antibody titers following the most recent infection (infection ni
I(t)) prior to time t that comes 
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from a gamma distribution with mean parameter γm and variance parameter γv; δ
i, ψ = ni
I(t)
 is 
the rate of decay of the temporary antibodies and comes from a gamma distribution with 
mean parameter δm and variance parameter δv. As with the permanent rise in titers, 
K(ψ = ni
I(t), s) allows differential antibody responses for primary infections: K(ψ, s) = η if it 
is a primary infection (i.e., ψ=1) and s is the infecting serotype; K(ψ, s) = 1 otherwise. 
Additional work is needed to understand if alternative functional forms for the rise and 
decay in antibody titers may further refine how antibodies behave following infection.
4.4.3. Overall trajectory of antibody titers: Under these assumptions, and an additional 
linearity assumption that the temporary and permanent rises are additive, antibody titers at 
blood draw k for serotype s in individual i is:
Ai, s, π, k = Qi, s(ψ = 1) + ⋯ + Qi, s ψ = ni
I(t = τi, π = k
A ) + Ri, s t = τi, π = 1
A ∣ Hi(t = τi, π = k
A ) + ⋯
+ Ri, s t = τi, π = k
A ∣ Hi(t = τi, π = k
A )
4.5. Infection history model—We first assume that both the number of infections and 
the timing of infections are known. This assumption will subsequently be relaxed. We 
assume that each individual can get infected up to four times (once by each serotype). An 
individual’s history of infection depends on seasonality in dengue transmission and 
differences in the force of infection across years. For a particular time t, the force of 
infection is assumed to be:
λ(t) = λ · β ∣ t ∣ · 1 + δ · cos ζ +
2πt
365
where λ̄ is a parameter that represents the mean daily force of infection in 1998 (the first 
year of the study) and β[t] is the mean force of infection in year |t| as compared to that in 
1998.
For an individual i, the contribution to the likelihood for periods prior to any infection the 
probability of their infection history can be broken down into periods of infection and 
periods without infection. Individuals only contribute to the likelihood during their time in 
the study.
For each infection that occurs at time t, the contribution to the likelihood is:
log (1 − exp −λ(t) )
For each individual, each day during which no infection occurs, the contribution to the 
likelihood in respect of serotype s is:
exp(−λ(t)) - where more than 90 days have passed since an infection by any serotype and the individual has not previously been infected by serotype 
s
0 - otherwise, including periods when the individual is not part of the study
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The presence of the 90-day window where no infection can take place avoids there being 
more than one infection event between two blood draws. This period is substantially shorter 
than the estimated period of cross-protection between serotypes of 2 years34.
4.5.1. Context of full observation: In the context of full observation, the probability of the 
history of infection for individual i can be given as:
P Hi(t = τi, π = k









λ(u) du 1 − exp ( − λ(τi, k








I  represents the time of birth and Ti the time point at which individual i leaves the 
study (defined as the day of their final blood draw). We assume the same λ(t) for all 
serotypes.
4.6. Situation of imperfect observation—In practice, we do not know the infection 
history of all individuals. Many infections will have occurred before individuals entered the 
study. In addition, there are likely to be many subclinical infections that would not have been 
detected through active surveillance. In addition, active surveillance only operated 5.5 
months of every year. Infections outside these periods would also have been missed 
(irrespective of symptoms).
4.6.1. Unobserved infections prior to recruitment: For the infection history of individuals 
before they enter into the study, we estimate a baseline titer Ai, s(t0) that represents the titer 
to serotype s one year prior to the first blood draw. As we assume linearity, such that the 
temporary and permanent titers of successive historic infections sum up to give the titer at a 
moment in time, this estimated baseline titer allows us to incorporate the impact of historic 
infection events up one year prior to enrollment but means we do not need to infer infection 
events before that time. Individuals that are naïve at baseline (defined as those with no 
measured titers to any serotype at the first blood draw) are given a baseline titer of 0. For an 
individual with no infection events during the study period, Ai, s(t)= i, s(t0) for all t.
4.6.2. Use of data augmentation for undetected infections or serotype during study: In 
the context of full observation during the study period, each individual would have the 
serotype and time from each infection, {si,ψ, τi,ψ}, known. In the setting of undetected 
infections or detected infections but infecting serotype is unknown (such as when 
symptomatic infections are only detected through IgM ELISA and therefore the serotype is 
unknown), we can use a Bayesian data augmentation framework. In this framework, the 
incompletely observed {si,ψ, τι,ψ} pairs are incorporated and considered as nuisance 
parameters. The joint posterior distribution of the parameters and the augmented data is 
explored via reversible-jump MCMC sampling.
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If we call y = si, ψ
∗ , τi, ψ
∗
i = 1, ..N, ψ = 1, …ni
∗(t = ∞)
 the observed data, z = 
{si, ψ, τi, ψ}i=1, … N, ψ = 1, … ni(t=∞) the full data (made up of the observed data and the 
augmented data), the joint posterior is:
P(z, θ ∣ y) ∝ P(y ∣ z) · P(z ∣ θ) · P(θ)
P(y|z) represents the observation model, P(z|θ) is the titer model outlined above and P(θ) 
gives the prior distribution of the parameters.
The observation model makes sure that the augmented datasets are consistent with the 
observed data by having a value of 1 (if consistent) or 0 (if inconsistent). Consistent 
augmented data have the following characteristics:
i. No individual is infected during the study period by the same serotype more than 
once
ii. No individual is infected more than once during a 90 day period
Note that, as DENV-titer responses to non-DENV flaviviruses such as Zika and Japanese 
encephalitis are likely to be smaller that to DENV infections, such exposures are unlikely to 
be detected by our model and incorporated as measurement uncertainty instead.
4.6.3. Date of symptom onset, date of infection and date of titer rise: For all detected 
(symptomatic) infections, we only detect the date of symptom onset and not the date of 
infection. To obtain the day of infection for symptomatic cases we subtract a fixed period of 
7 days from the day of symptom onset, representing the median incubation period for 
dengue35. Titers may also not rise on the day of symptom onset (due to recall bias in when 
symptoms started or individual level variability). For symptomatic infections, we 
approximate the true, unobserved day of titer rise using augmentation, where we define 
consistent augmented data for which the day of titer rise is within ten days of the reported 
date of symptom onset. For augmented (undetected) infections, we assume that the day of 
titer rise following infection always occurs 11 days after the day of infection, which 
represents an approximate estimate of the time between infection and day of titer rise: 
calculated as the sum of the median incubation period for dengue (seven days) and the 
median time between symptom onset and titer rise for the detected infections (four days).
4.6.4. Impact of uneven data collection through time: This cohort used a rolling 
recruitment approach, which maintained an approximately constant sized population and 
constitutes an important strength compared to cohorts whose size may be strongly affected 
by participant dropout. As individuals only contributed to the likelihood for their period of 
inclusion in the cohort and dropout is not expected to depend on the history of infection, we 
do not expect that the turnover of participants in the cohort will bias parameter estimates. 
This was demonstrated in a simulation study where we were able to recover true parameters 
for a simulated cohort with a similar design (see Section 4.8).
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4.6.5. Prior distributions: We use a log-normal distribution with log-mean 0 and log-
variance of 1 for the parameters: mean and variance in the permanent rise in log2-titers (ωm, 
ωv), mean and variance in the temporary rise in log2-titers (γm, γv), mean and variance in 
the decay in log2-titers per day (δm, δv), difference in rise for infecting vs. non infecting 
serotype (primary infection only) (η), measurement error (σ), DENV2-4 bias (χ2, χ3, χ4), 
daily force of infection in 1998 per serotype (λ), relative force of infections versus 1998 for 
1997 (β0) and 1999–2002 (β2-β5) and the two seasonality parameters (δ and ζ).
4.7. Estimation using MCMC—We develop a Markov chain Monte Carlo approach to 
explore the joint posterior distribution of parameters and the augmented data with the 
following steps:
i. Metropolis-Hastings update for the model parameters θ in turn with the updates 
performed on a logarithmic scale. The step size of the proposals was adjusted to 
obtain an acceptance probability of 20–30%. As the vast majority of infections 
are undetected, when updating the six parameters that determine the rise and 
decay of antibodies (namely ωm, ωv, δm, δv, γm, γv,), we calculate the 
likelihood using only the titers from one month prior to and year post the 
symptomatic (and therefore detected) infections. This approach assumes that the 
rise and fall in titers from all infections come from the same distributions, 
irrespective of symptom status. More work is needed to understand if whether or 
not an infection leads to symptoms changes the titer dynamics following that 
infection.
ii. For the symptomatic cases, as the day of titer rise may not fall exactly at the 
recorded day of symptom onset we use an independence sampler to update the 
day of titer rise. At each iteration, the day of the titer rise was updated for 100 
randomly chosen symptomatic infections. Candidate values were chosen using a 
uniform distribution between 10 days prior to and 10 days post the recorded date 
of symptom onset.
iii. Independence sampler for the identity of the infecting serotype for the 62 
symptomatic infections where the serotype was not identified. At each iteration, 
the serotype for each of these infections is updated with equal probability across 
the four serotypes.
iv. Independence sampler for the identity of the infecting serotype for the 
undetected infections. At each iteration, the serotype for 500 randomly chosen 
undetected infections is updated with equal probability across the four serotypes.
v. Independence sampler for the dates of titer rise for undetected infections. At each 
iteration, the day of infection is updated for 1000 randomly chosen undetected 
infections. For each infection, the proposal is a uniform distribution between one 
year prior to entry into the study and the day of the final blood draw.
vi. Independence sampler for the baseline titers for each individual. At each 
iteration, the baseline titer for one serotype is updated for 1000 randomly chosen 
individuals. The proposal distribution is a random uniform distribution between 0 
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and 10. All individuals that are naïve at baseline (i.e., those with no titers to any 
serotype at the first blood draw) are forced to have a baseline titer to 0 for all 
four serotypes.
vii. Reversible jump –MCMC to add/remove unobserved infection events. As Hi(tj) 
is unobserved, we use a Bayesian data augmentation approach that treats it as a 
nuisance parameter. Rather than attempting to definitively identify whether an 
infection occurred or not, these approaches allow us to incorporate the 
uncertainty of the presence and timing of these events. We use reversible jump 
MCMC (RJ-MCMC) to add and remove infection events. Each step to add 
undetected infections proceeds as follows:
a. Randomly draw individual.
b. Draw a candidate date for the infection event using a uniform 
distribution from 1 year prior to their first blood draw to the day of their 
final blood draw.
c. Draw a candidate serotype of infection with the probability of each 
serotype being 0.25.
d. Update the number, date and serotype of infections for that individual.
For the removal of undetected infections, we use a similar approach:
a. Randomly draw individual.
b. If that individual has undetected infections, randomly select one of their 
infections with equal probability (if they have no infections move to the 
next individual).
c. Update the number, date and serotype of infections for that individual 
by removing that infection.
4.8. Evaluation of model using simulated data—In order to evaluate the ability of 
the model to accurately estimate the parameters in a scenario when only a minority of 
infections are observed, we use the same modelling framework on a random subset of 1,000 
individuals from the study with subsequent changes in titers, We include the actual start date 
and the end date for these individuals (i.e., when they entered and left the cohort). We 
simulate infections in these individuals based on known parameters. We then randomly 
‘unobserve’ 70% of infections to reflect undetected infections. We then estimate the 
parameters using our framework and compare them to the underlying true parameters.
4.9. Sensitivity analysis using school-specific force of infection parameters—
The force of infection exerted on individuals may differ across schools, resulting in non-
independence between individuals attending the same school. To assess the impact of any 
such correlation on our parameters, we performed a sensitivity analysis where we included a 
separate force of infection parameter for each school. In this model the force of infection 
exerted on an individual that attends school sch is:
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λ(t, sch) = λ · β ∣ t ∣ · β ∣ sch ∣ · 1 + δ · cos ζ +
2πt
365
where λ̄ is a parameter that represents the mean daily force of infection in 1998 in school 1, 
β[t] is the mean force of infection in year |t| as compared to that in 1998 and β[sch] is the 
mean force of infection for school sch as compared to school 1.
4.10. Alternative functional forms for the decay in titers—Alternative functional 
forms for the decay in antibody titers exist. In particular, biphasic models that model both 
short-term antibody decay and longer-term antibody decay with different exponential decay 
rates have been shown to work well in other systems, such as malaria36. The biphiasic form 
is captured by:
Titert = θ1 · (θ2 · exp ( − θ3t) + (1 − θ2) · exp ( − θ4t))
where θ1, θ2, θ3 and θ4 capture the decay of the titers. To explore whether this biphasic 
form may further refine how antibodies behave following infection here, we fitted both 
exponential decay and biphasic models to the observed infections using the observed titers 
following detected PCR-confirmed infections and the dates of symptom onset. We found 
largely consistent results in the two models (Extended Data Figure 1). As exponential decay 
is the more parsimonious model, we retained this form for the final analysis. Nevertheless, 
structural uncertainty in the model used for the analysis remains, which will not be 
represented within the confidence intervals for the parameters.
4.10. Estimation of impact on titers on infection and disease
4.10.1. Estimation of impact of mean titers on infection: We use the augmented times and 
serotypes of infection from 100 model iterations to reconstruct the antibody titer trajectories 
for each individual. For each augmented dataset we extract the mean titer across all four 
serotypes for each day and whether they got infected in the following day or not. Person-
time in individuals who were considered not susceptible (i.e., had been infected in the prior 
90 days) was excluded. To explore the relationship between mean titer and the probability of 
infection we conducted logistic regression where we used a polynomial spline of order 2 for 
the mean titer (determined as the optimal model through comparison of different polynomial 
models by AIC). To account for sampling uncertainty, in each reconstructed dataset we use a 
bootstrap approach to sample all individuals with replacement and then re-perform the 
logistic regression each time. We present the mean and 95% confidence intervals from the 
resultant distribution of the logistic model estimates of the probability of infection for each 
titer obtained from across the model iterations.
4.10.2. Estimation of impact of mean titers on disease outcome: We explore the 
relationship between mean titer and the probability of having different disease outcomes. We 
consider three different outcomes: symptomatic infection (irrespective of severity), 
hospitalization and DHF. We use the same approach as in Section 4.9.1. but only consider 
titers during the active surveillance windows and whether or not individuals had an infection 
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the following day that led to the outcome of interest. For each outcome, we conduct logistic 
regression where we use a polynomial spline of order 2 for the mean titer (consistently 
determined as the optimal model through comparison of different polynomial models by 
AIC). We use a bootstrap approach to sample all individuals with replacement and then re-
perform the logistic regression each time and identified the mean and 95% confidence 
intervals from the resultant distribution for the estimates of the probability of having an 
infection that led to the outcome of interest for each titer obtained from across the model 
iterations.
4.10.3. Estimation of impact of mean titers on disease outcome, conditional on being 
infected: For those that became infected during the active surveillance windows, we fit 
logistic models to the mean titers and whether or not the disease outcome occurred. We 
looked at three outcomes: any symptomatic illness, hospitalization and DHF. For each of the 
three outcomes, we compare an intercept only model with models with a polynomial spline 
up to order 2. To account for sampling uncertainty, in each reconstructed dataset we use a 
bootstrap approach to sample all individuals who had an infection during the surveillance 
windows with replacement and then re-perform the logistic regression each time. We present 
the mean and 95% confidence intervals from the resultant distribution of the logistic model 
estimates of the probability of infection for each titer obtained from across the model 
iterations.
4.10.4. Estimation of impact of mean PRNT titers on disease outcome, conditional on 
being infected: PRNT titers are available for a subset of 1,771 blood draws. For those that 
became infected during the active surveillance windows and PRNT titers are available in the 
six months window prior to infection, we fit logistic models to these mean PRNT titers from 
that six-month time frame and whether or not the disease outcome occurred. We looked at 
three outcomes: any symptomatic illness, hospitalization and DHF. For each of the three 
outcomes of interest, we compare an intercept only model with models with a polynomial 
spline up to order 2. To account for sampling uncertainty, in each reconstructed dataset we 
use a bootstrap approach to sample all individuals who had an infection during the 
surveillance windows with replacement and then re-perform the logistic regression each 
time. To account for the fact that individuals and serum samples may not have been 
completely selected at random for PRNT testing (e.g., preferential testing of those with 
symptomatic disease), we adjusted our estimate for the probability of sampling conditional 
on the outcome of interest.
From the logistic regression described above, we can extract the probability of the outcome 
of interest given a particular PRNT titer and that a PRNT was conducted. Using Bayes rule 
we can write down:
P(outcome ∣ titer, PRNT done) = P(PRNT done ∣ outcome, titer)P(outcome ∣ titer)P(PRNT done ∣ titer)
as the PRNT titer (or the HI titer) was not taken into account in the section process for 
choosing whether or not a PRNT was done, this becomes:
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P(outcome ∣ titer, PRNT done) = P(PRNT done ∣ outcome)P(outcome ∣ titer)P(PRNT done)
As we are interested in P(PRNT done|outcome), we can reorder this equation to:
P(PRNT done ∣ outcome) = P(outcome ∣ titer, PRNT done)P(PRNT done)P(outcome ∣ titer)
We therefore multiply our logistic model outcomes by the following adjustment factor:
adj . factor = P(PRNT done)P(PRNT done ∣ outcome)
P(PRNT done) is calculated as the proportion of all infection events where a PRNT was 
conducted in the prior 6 months from the infection and P(PRNT done|outcome) is calculated 
as the proportion with the outcome of interest where PRNTs were conducted in the prior 6 
months. We present the mean and 95% confidence intervals from the resultant distribution of 
the logistic model estimates of the probability of infection for each titer obtained from 
across the model iterations.
4.10.5. Estimation of impact of year and age on mean titers on disease outcome: We 
used a logistic regression approach to explore the impact of year of infection and the age at 
the time of infection. To explore the impact of year, we take each augmented dataset in turn 
and sample all the individuals with replacement to incorporate sampling uncertainty. We 
then regress the year of infection (as a categorical variable) on whether the outcome Yi, t 
occurred:
logit Yi, t = β0 + β1 · Yeari, t
where Yeari, t is the year (1998, 1999, 2000, 2001 or 2002) within which day t occurred for 
individual i. We conducted separate regression where the outcome was an infection event 
(irrespective of whether the infection led to symptoms), symptomatic infection events 
(irrespective of disease severity), hospitalization and development of dengue hemorrhagic 
fever. For the last three models we only considered data during the active surveillance 
windows, as we do not know the symptom status of infections outside these windows. To 
explore the impact of age, we dichotomized the age of individuals as being less than or 
greater than 9 (the Sanofi Pasteur vaccine is not recommended for individuals under 9). We 
then performed the regression:
logit Yi, t = β0 + β1 · Agei, t
where separate models for the same four outcomes, Yi, t, were peformed. Finally, we built 
multivariable models that also accounted for mean titer using a polynomial of order 2:
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logit Yi, t = β0 + β1 · Agei, t + β2 · Titeri, t + β2 · Titeri, t
2
4.11. Impact of titer on outcome using cox proportional hazard models—In the 
context of small probabilities of an event occurring and short time intervals between 
readings, logistic regression will give consistent results with that from cox proportional 
hazards models that specifically takes the non-independence of titer observations from the 
same individuals into account17. To demonstrate the consistency of the two approaches we 
estimate the impact of titer on our four outcomes (infection, symptomatic infection, 
hospitalized infection and DHF infection) using a time-varying cox proportional hazards 
model, specifically incorporating clustering of observations by individual37. We used 100 
augmented datasets. For each augmented dataset we extract the mean titer across all four 
serotypes for each day and whether they got the outcome of interest in the following day or 
not. For the disease specific outcomes (any symptomatic disease, hospitalized infection and 
DHF infection), we only used time points during the surveillance windows. We then 
calculated the impact of the mean titer (polynomial of order 2) on the relative hazard of 
infection, incorporating a clustering id per individual using the survival package in R37. We 
then calculate the mean effect of titer on the outcome of interest by averaging the estimates 
across the reconstructed datasets.
To compare our results using logistic regression, we multiply the annualized estimate of a 
titer x on the risk of the outcome (calculated as 1-exp(-365x)) by the estimated baseline 
hazard for those with a measured titer of 0 (calculated as the proportion of infections in time 
points with a measured titer of 0). We find that the results are almost identical (Extended 
Data Figure 6). As the logistic model approaches allow us to directly estimate the underlying 
probability of the outcome, it is preferred.
5. Survival analysis
5.1. Annualized probability of infection using titer data only—Over 100 
reconstructed datasets, we initially identify all individuals who experienced an infection 
(irrespective of disease severity). We then identify the setpoint antibody load for that 
infection as the mean titer 1 year following infection as predicted by our model. Individuals 
were divided into two groups, those with a setpoint antibody load ≤3 and those with a load 
>3. For each individual in each titer group, we use the logistic model from 4.9.1 to predict 
the daily probability of a subsequent infection based on the mean titers each day following 
the initial infection. We also calculated the daily probability of experiencing an infection that 
leads to DHF using the logistic model from 4.9.2. We annualize the predicted probabilities 
of subsequent infection by using the conversion 1-exp(-365x) where x is the daily 
probability of infection. We present the mean annualized probabilities across all individuals 
and over all the reconstructed datasets.
5.2. Kaplan-Meier analysis—For individuals who experienced an infection, we calculate 
Kaplan-Meier survival curves for experiencing a subsequent infection (both irrespective of 
disease outcome and for DHF only). Over 100 reconstructed datasets, we identify all 
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individuals who experienced an infection event. We then identify the setpoint antibody load 
for that infection as the mean titer 1 year following infection as predicted by our model. 
Individuals were divided into two groups, those with a setpoint antibody load ≤3 and those 
with a load >3. To incorporate sampling uncertainty we resample all individuals with 
replacement. For each group we then calculate Kaplan-Meier survival curves. We present the 
mean and 2.5 and 97.5 quantiles from the resultant distribution.
6. Prediction of DHF outcome using mean titer
We assess the ability of our logistic model to discriminate between those who developed 
DHF and those who did not using leave one out cross validation.
6.1. DHF outcome among all cohort participants—For each reconstructed dataset, 
taking each DHF case in turn, we initially identified all individuals who were in the cohort at 
the same time as the DHF infection with detectable titers who did themselves not have a 
DHF infection within a 1-year period. We then randomly selected one of those individuals 
and used the titer from that day. Once we had selected a matched control for each DHF case, 
we calculated the ROC using leave one out cross validation. To do this we removed each 
individual in turn from the dataset (including both the cases and the controls) and 
recalculated the relationship between mean HI titer and DHF infection using all the 
remaining titer readings. We then predicted the probability that the held-out case had a DHF 
infection. The ROC was calculated using these probabilities across individuals. We present 
the mean ROC from across 100 reconstructed datasets.
6.2. DHF outcome among all infections—We assessed the ability of our model to 
discriminate between those who did and did not develop DHF following infection. For a 
reconstructed dataset, we identified all individuals with detectable titers prior to infection 
who had a DHF infection and those that did not have a DHF infection (i.e., those with an 
infection during the surveillance windows that did not develop DHF). For each infection 
event, we identified the mean titer the day before infection. We then used leave one cross 
validation as described above to assess our ability to identify those that went on to develop 
DHF from those that did not. We present the mean ROC from across 100 reconstructed 
datasets.
7. Clustering of infections by school
For additional model validation, we explore whether augmented infections occurred in the 
same schools at around the same time as observed cases, despite no information on location 
being provided to the model.
7.1. Clustering of subclinical infections within schools—To explore the clustering 
of subclinical with symptomatic infections in schools, we use the tau clustering statistic 31,38 
to calculate the odds of observing an subclinical infection (irrespective of serotype and 
infection parity) within a set time period (t1, t2) of a symptomatic infection within the same 
school relative to the odds of observing an subclinical infection in a different school within 
the same time window.
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Nsymp ∑ j = 1
Nasymp I(schi j = 1, t1 < ∣ si j ∣ < t2)
∑i = 1
Nsymp ∑ j = 1
Nasymp I(schi j = 0, t1 < ∣ si j ∣ < t2)
where Nsymp and Nasymp are the number of symptomatic and subclinical infections within 
any model iteration, schij is equal to one if individuals i and j go to the same school and 0 
otherwise, sij is the time between infections. We varied the time window between 0–90 days, 
90–180 days and greater than 180 days.
7.2. Clustering of serotypes within schools—We explore whether the augmented 
serotypes that were assigned to subclinical primary infections (serotypes could not reliably 
be assigned in post primary infections due to cross reaction) were consistent with the 
serotypes of the symptomatic infections of individuals within the same school for different 
periods of time.
For augmented primary infections that are consistently of the same serotype (defined as 
>50% of augmented datasets have a primary infection in the same individual caused by the 
same serotype in the same six-month time window), we calculated the odds that an 
augmented primary infection that occurs in the same school and within a fixed time window 
of a PCR-confirmed case is of the same serotype relative to the odds that an augmented 








Nsymp ∑ j = 1
Nasymp I(schi j = 1, t1 < si j < t2, seri j = 1)
∑i = 1
Nsymp ∑ j = 1
Nasymp I(schi j = 1, t1 < si j < t2, seri j = 0)
π3(t1, t2) =
∑i = 1
Nsymp ∑ j = 1
Nasymp I(schi j = 0, t1 < si j < t2, seri j = 1)
∑i = 1
Nsymp ∑ j = 1
Nasymp I(schi j = 0, t1 < ∣ si j ∣ < t2, seri j = 0)
where serij is equal to 1 if i and j go to the same school and 0 otherwise. We varied the time 
window between 0–90 days, 90–180 days and greater than 180 days.
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7.3 Uncertainty—To incorporate sampling uncertainty into our estimates, for each model 
iteration we randomly selected all infection events with replacement before calculating the 
tau estimates. Ninety-five percent confidence intervals were calculated from the 2.5% and 
the 97.5% quantiles of the resultant distribution across all model iterations.
8. Different approaches to identify infections using simple cut-points
To assess the sensitivity and specificity of the current approach to identify infections based 
on titer differences across two blood draws, we simulated titer trajectories where infections 
did and did not take place.
8.1. Simulated titers where infections did take place—We used the following 
algorithm:
i. Randomly draw MCMC iteration
ii. Randomly divide the population of individuals who had at least one infection in 
two: ‘model fit’ individuals and ‘held out’ individuals.
iii. Of the model fit individuals, randomly draw an individual i
iv. Identify the parameters for the antibody dynamics for the first infection for that 
individual (i.e., ψi,τ=1, γi,τ=1, ωi,τ=1) and the baseline titer Ai,s(t0) from that 
MCMC iteration. The true titer for each serotype will be Ai,s(t0).
v. Calculate the measured titer for each serotype using a random draw from a 
normal distribution with mean Ai,s(t0) and standard deviation σ, where σ 
represents the measurement error for the assay. Under scenarios of a discrete 
assay, the measured titer is also rounded down to the nearest integer.
vi. Draw an infection time point using a uniform distribution between 0 and tmax 
where tmax represents the time of the second blood draw.
vii. Calculate the true titer at tmax for each serotype, Ai,s(tmax)
viii. Calculate the measured titer using a random draw from a normal distribution 
with mean Ai,s(tmax) and standard deviation σ. Under scenarios of a discrete 
assay, the measured titer is also rounded down to the nearest integer.
8.2. Simulated titers where infections did not take place
i. Randomly draw MCMC iteration
ii. Randomly divide the population of individuals who had at least one infection in 
two: ‘model fit’ individuals and ‘held out’ individuals.
iii. Of the model fit individuals, randomly draw an individual i
iv. Identify the baseline titer Ai,s(t0) from that MCMC iteration. The true titer for 
each serotype will be Ai,s(t0).
v. Calculate the measured titer for each serotype using a random draw from a 
normal distribution with mean Ai,s(t0) and standard deviation σ, where σ 
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represents the measurement error for the assay. Under scenarios of a discrete 
assay, the measured titer is also rounded down to the nearest integer.
vi. Calculate a second measured titer using a random draw from a normal 
distribution with mean Ai,s(t0) and standard deviation σ. Under scenarios of a 
discrete assay, the measured titer is also rounded down to the nearest integer.
8.3. Different assays
8.3.1. Current approach: The current approach is to see whether there is a four-fold rise 
between blood draws in any of the four serotypes using the discrete HI assay.
8.3.2. ‘Mean’ approach: This approach is to first calculate the mean across the four 
serotypes at each time point and then compare the mean titers across two time points to 
identify whether infections have occurred or not.
8.3.3. ‘Continuous assay’ approach: Some assays give titers on a continuous scale (and not 
discretized like the HAI assay). In this approach, as with the ‘Mean’ approach, we initially 
calculate the mean titer across the four serotypes at each time point and then compare the 
mean titers across two time points to identify whether infections have occurred or not.
8.4. Assessment of the different assays by time between blood draws and 
error in assay—Using the simulation approaches set out above we obtained 10,000 
individuals with pairs of measured titers (with one titer for each serotype) where an infection 
did take place in between the titer measurements and a further 10,000 individuals with pairs 
of measurements where no infection took place. We varied the time between blood draws 
(tmax) between 10 days and 400 days and the error in the assay (σ) between 0.1 and 1. For 
each resultant dataset we used the held-out dataset (i.e., those individuals not included in the 
model fitiing) to calculate the sensitivity and specificity under each of the approaches in 6.3. 
Each time, we also identified the cutpoint that maximized the sensitivity while maintaining 
at least 95% specificity. We performed a separate analysis where we identify cutpoints to 
maximize sensitivity while maintaining 99% specificity.
9. Comparison between PRNT and HI titers
For 1,771 blood draws, both plaque reduction neutralization tests and HIs were conducted. 
We compare the mean PRNT log titer across the four serotypes with the mean HI log titer 
from the four serotypes and fit a line through the two using linear regression. We compared 
different polynomial models up to order 2 and used the best fitting one as determined by 
AIC.
10. Comparison with Sanofi Pasteur vaccine titers
To explore the potential impact of the Sanofi vaccine we extracted the geometric mean 
PRNT titers following vaccination for both seronegative and seropositive individuals who 
were vaccinated in Latin America21. The extracted values for PRNT titer, 28 days after the 
second injection are (see Table S8 in 21) are shown in Table S8.
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The values 28 days after the third injection are also available and are 81 for those 
seronegative prior to vaccination and 658 for those seropositive prior to vaccination21. We 
plot these values on a plot of the relationship between HI titer and PRNT titer from our 
assays (Figure 4D).
11. Ethical approval
The cohort protocol was approved by the institutional review boards of the Thai Ministry of 
Public Health, the Office of the US Army Surgeon General, and the University of 
Massachusetts Medical School. Informed consent was obtained from participants and their 
parents/guardians. No personally identifiable information was available to the researchers 
for the presented analysis.
12. Code availability statement
c++ code is available from the corresponding author on request.
Extended Data
Extended Data Figure 1. Comparison of biphasic versus exponential decay
Biphasic and exponential decay curves fitted to HI antibody measurements following 
observed symptomatic infections.
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Extended Data Figure 2. Variability in titer responses and measurement error and bias by 
serotype
(A) Variability in titer responses. Violin plots showing median (black square), 25% and 75% 
quantiles (thick black line) and 95% distribution (in grey) of net titer rise at different time 
points following infection (N=1,420) (B) Estimated underlying differences across serotypes 
in the measurement of antibody levels by hemagglutination inhibition assay over and above 
that attributable to infection (DENV1 is reference) with 95% credible intervals (fitted to data 
from 140,612 titer measurements). (C) Mean estimated error in the hemagglutination 
inhibition assay estimated with 95% credible intervals using our model results (grey) and 
empirically derived (blue) from 795 repeated measurements on the same serum compared to 
that previously empirically derived estimated for plaque reduction neutralization tests 
(PRNTs) (blue).
Extended Data Figure 3. Serotype distributions
(A) Distribution of serotypes by year comparing the detected symptomatic infections by 
PCR and the augmented primary infections where we could confidently assign the serotype 
(>50% of model iterations inferring the same serotype). We could confidently assign the 
serotype in 60% of instances. (B) Serotype distribution for detected symptomatic primary 
infections and augmented subclinical primary infections where the infecting serotype could 
be confidently assigned (>50% of model iterations inferring the same serotype). (C) 
Distribution of serotypes by year comparing the detected symptomatic infections by PCR 
and the augmented primary infections using a more stringent cutoff that >75% of model 
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iterations infer the same serotype. In this scenario we could confidently assign the serotype 
in 32% of instances.
Extended Data Figure 4. Cox proportional hazards model versus logistic regression
Comparison of results using time varying cox proportional hazards model (dashed line) with 
that from logistic regression (solid line) for the annualized probability of (A) infection, (B) 
developing any symptoms, (C) being hospitalized and (D) developing DHF as a function of 
the mean measured antibody titer across all serotypes at the time of exposure using titer data 
from all study subjects (N-3,451). The open circles on the left represent primary infections 
(i.e., those with no detectable titers to any serotype prior to exposure). The shaded regions 
represent 95% bootstrap confidence intervals. To calculate probabilities, the relative hazards 
from the cox model are multiplied by the baseline hazard for those with measured titers of 0 
(calculated as proportion of person-time with an infection time among those with measured 
titers of 0).
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Extended Data Figure 5. Receiver Operating Characteristic to identify DHF infections
Ability of modelled relationship between measured HI titer and risk of DHF to identify 
those with DHF using those with DHF compared to randomly selected matched controls 
from individuals in the cohort who had detectable titers at the same time (N=36 with DHF 
with the same number of matched controls).
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Extended Data Figure 6. Probability of disease as a function of HI and PRNT titer
Probability of disease as a function of mean titer across the four types at the time of 
infection. (A) For those infected during the surveillance windows, the probability of 
developing any symptoms as a function of mean titer (N=781). (B) For those infected during 
the surveillance windows, the probability of being hospitalized (N=781). (C) For those 
infected during the surveillance windows, the probability of developing DHF as a function 
of mean titer (N=781). (D) For those infected during the surveillance windows (N=781), the 
probability of developing any symptoms as a function of mean PRNT titer. (E) For those 
infected, the probability of being hospitalized as a function of mean PRNT titer. (F) For 
those infected, the probability of developing DHF as a function of mean PRNT titer. In each 
panel, the open circles on the left represent primary infections. The shaded region represents 
95% confidence intervals.
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Extended Data Figure 7. Population-level distribution of titers by birth cohort and age
(A) Proportion of cohort who are naïve as a function of time. (B) Proportion of cohort who 
are naïve as a function of age. Proportion of cohort with titers above risk zone (i.e., greater 
than 3) as a function of time (C) and age (D).
Extended Data Figure 8. Receiver Operating Characteristic for infection detection under 
different testing protocols
The ROC for different assay approaches and time between blood draws calculated from 
100,000 simulated titer responses. (A) Single serotype assay – if HIs are conducted for just a 
single serotype at two time points. (B) HIs conducted against all four serotypes. Infections 
are considered to occur if the ratio of any of the four titers at time point 2 versus time point 1 
is greater than the threshold value. (C) HIs conducted against all four serotypes. Infections 
are considered to occur if the ratio of the mean of the four titers at time point 2 versus the 
mean at time point 1 is greater than the threshold value.
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Extended Data Figure 9. Performance of assay dependent on time between blood draws and 
measurement error
Optimization of assays in detection of events where specificity is maintained at >95%. We 
explore the performance of three different assay testing protocols: current practice where 
infection events are defined as a rise above a cut-point in any serotype across two blood 
draws (A), ‘mean approach’ where the mean across all serotypes is first calculated before 
comparing across time points (B), ‘mean approach’ where titers are available on a 
continuous scale (C). For each protocol, we identify the optimal cut-point for a range of 
assay measurement errors from 100,000 simulated titers based on the fitted titer responses 
from infections in our study population, that maintains a specificity of >95% (top row). We 
then calculate the sensitivity of the approach for different time intervals between blood 
draws using 50% held out data (bottom row). (D)–(F) Same as (A)–(C) but using a more 
stringent 99% cut-off.
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Extended Data Figure 10. Clustering of symptomatic (N=274) and subclinical cases (mean N=507 
across 100 reconstructed datasets) by school by time and serotype
(A) Probability of observing an augmented subclinical infection (irrespective of serotype) 
occurs at different time intervals within the same school of a detected symptomatic case 
relative to the probability of observing an augmented subclinical infection occurring in a 
different school in that same time interval. (B) For augmented primary infections that are 
consistently of the same serotype (defined as >50% of augmented datasets have a primary 
infection in the same individual caused by the same serotype in the same six-month time 
window). Probability that an augmented primary infection that occurs within a fixed time 
window of a PCR-confirmed case and in the same is of the same serotype relative to the 
probability that an augmented primary infection that occurs within the same time window in 
a different school is of the same serotype. Note that the modelling framework can only allow 
differentiation of serotypes for primary infections. Cross-reaction prevents differentiation in 
post-primary infections. Overall, 60% of primary infections have a consistent serotype for a 
primary infection across augmented datasets. Each boxplot presents the 2.5%, 25%, 75% 
and the 97.5% quantiles of the distribution as well as the mean.
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Figure 1. Titer responses following infection
(A) Measured (dots) and model fit (lines) for three example individuals. Each dot represents 
the mean titer across the four serotypes. The pink shaded regions are periods of active 
surveillance. The solid blue arrows represent confirmed symptomatic dengue infections. The 
open blue arrows represent estimates of timing of subclinical infections from an augmented 
dataset. During the active surveillance windows, these augmented infections represent 
subclinical infections whereas outside the surveillance window, it is unknown if the 
individual had symptoms. (B) Serotype distribution of PCR confirmed symptomatic 
infections (DENV1 – green, DENV2 - blue, DENV3 - maroon, DENV4 – orange, unknown 
serotype – black). The grey bars represent the estimated distribution of infections not 
detected from active surveillance. The periods of active surveillance are in pink (5.5 months 
per year). (C) Model fit (lines) and observed (dots) titers pre and post infection for primary 
infections (infecting serotype in blue, non-infecting serotypes in red) and post-primary 
infections (green). (D) Mean difference between observed log2-titer at different time points 
following infection with that at 1 year for all augmented and observed infections (average of 
1,421 total infections across 100 reconstructed datasets) with 95% confidence intervals. (E) 
Titer ratio of the infecting to the mean of the three non-infecting serotypes before and after 
symptom onset with 95% confidence intervals for the 217 individuals with symptomatic 
infections where infecting serotype detected (N=3,366 total titer measurements).
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Figure 2. Probability of infection and disease as a function of titer
Annualized probability of (A) infection, (B) developing any symptoms, (C) being 
hospitalized and (D) developing DHF as a function of the mean measured antibody titer 
across all serotypes at the time of exposure across all study subjects (N=3,451). The open 
circles on the left represent primary infections (i.e., those with no detectable titers to any 
serotype prior to exposure). The shaded regions represent 95% bootstrap confidence 
intervals.
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Figure 3. Risk of subsequent infection and disease following an infection event (from average of 
1,420 infections across 100 reconstructed datasets)
The probability of survival from subsequent infection (irrespective of disease outcome (A) 
and that lead to DHF (C)) as calculated from Kaplan-Meier for those with setpoint antibody 
titers of ≤3 (red) and >3 (blue) with 95% confidence intervals. The annualized probability of 
a subsequent infection (irrespective of disease outcome (B) and that lead to DHF (D)) at 
different time points following infection for those with setpoint antibody titers of ≤3 (red) 
and >3 (blue).
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Figure 4. Evolution of population risk, implications for vaccine and cohort design
(A) Proportion of study participants who have titers in risk zone (defined detectable log2-
titers ≤3) over the study period for different birth-cohorts (colored lines) and overall (black). 
The epidemic curve of all infections is in grey. (B) Proportion of study participants with 
titers in risk-zone as a function of age for different birth-cohorts (colored lines) and overall 
(black). (C) Performance of current assay testing protocol where infection events are defined 
as a rise above a cut-point in any serotype across two blood draws. (D) Relationship between 
PRNT titer and HI titer where both assays were performed (N=1,771 samples). The boxplots 
show 2.5, 25, 75 and 97.5 quantiles as well as the mean. Superimposed are the results from 
the Denvaxia vaccine for previously seronaive (blue) and seropositive (red) prior (open 
symbols) and post (filled symbols) vaccination.
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